Posttransplant lymphoproliferative disorder
Post-transplant lymphoproliferative disorder (PTLD), also referred as post-transplant lymphoproliferation disorder, represents a variety of conditions ranging from lymphoid hyperplasia to malignancy, included in the WHO classification of tumors of hematopoietic and lymphoid tissues. It can be a life-threatening fulminant disorder.
PTLD develops in no more than 2% of all patients who receive transplants, somewhat higher in pediatric patients . It is the second most common type of malignancy in post-transplant patients with two peaks demonstrated - at one-year post-transplant and at 4-5 years post-transplant . The incidence varies according to the type of transplant :
- small bowel: high
- pancreas: 12%
- heart and lung: 3-9%
- liver: 1-2%
- cardiac: 1-2%
- renal: 1-2%
- hematopoietic stem cell transplant: 0.6-1.2%
Some risk factors are recognized, including :
- Epstein-Barr virus seronegativity at the time of transplantation (which may explain why the incidence of PTLD is higher in children)
- concomitant cytomegalovirus infection
- allograft type
The immunosuppressive regime also affects the distribution of PTLD:
- azathioprine: more common CNS and allograft involvement
- cyclosporine or FK-506: gastrointestinal tract and lymph nodes
Clinical presentation is variable, both in symptomatology and severity, ranging from flu-like symptoms with fever and malaise to fulminant systemic disease . It of course also varies with the location of the PTLD (see below).
The time between transplant and development of PTLD is also variable, ranging from 1 month to 7 years , with most occurring within a year . As a general rule, patients who present late (>1 year) have more aggressive tumors with poorer prognosis .
Most PTLD specimens demonstrate a polyclonal B-cell Epstein-Barr virus (EBV) positive cell population . Monoclonal B-cell and T-cell small bowel lymphomas do occur in patients with organ transplants but are less frequent.
When PTLD develops in hematopoietic stem cell transplant recipients, it usually arises from the donor cells .
Macroscopically these tumors have been likened to uncooked fish flesh.
These tumors range from low-grade/benign lymphoid hyperplasia to high-grade malignant non-Hodgkin lymphoma.
PTLD may be focal or diffuse and can affect almost any organ system and even the allograft. It usually manifests as an extranodal disease, and it can occur in a variety of locations, including :
- liver: most common
- small bowel
- colon and stomach less common
- head and neck
- primary central nervous system PTLD
- osseous: rare
The range of appearances is large due to the number of possible sites. In general extranodal involvement is 3-4 times more common than nodal involvement, and resembles primary lymphoma of those organs :
- solid organs (liver, spleen, kidney)
- low density on CT
- diffuse infiltration
- circumferential wall thickening
- aneurysmal dilatation
- bowel obstruction uncommon
- usually homogeneous
- may centrally cavitate
- diffuse infiltration
- similar to lymphoma in the setting of HIV infection
- necrosis and hemorrhage more common than in run-of-the-mill primary CNS lymphoma
- non-specific nodal enlargement, similar to other lymphomas
- most commonly affecting mediastinum (either lymphadenopathy or anterior mediastinal mass) or retroperitoneum (either as lymphadenopathy or mass)
Treatment and prognosis
Treatment is variable and depends on the location and extent of disease. Options include :
- reduction of immunosuppression
- surgical resection of localized disease
- medical agents
- alpha interferon therapy
- antiviral therapy (limited success)
- IL-2 infusions
Prognosis depends on the grade of the lymphoma, and cell type: the low-grade lymphoid proliferation of polyclonal B-cell origin with EBV implication have a better prognosis than other cell types of higher grade. Five-year survival is ~35% .
Disease regression in response to a reduction in immunosuppression is a unique diagnostic feature of PTLD and distinguishes this condition from other malignant diseases. Patients should be closely monitored for allograft rejection.
The differential diagnosis would depend on the location of PTLD and is therefore broad: